Immupharma Plc (IMM) Ordinary 1p
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
ImmuPharma progresses P140 clinical programme with FDA
12 April 2023 14:13
(Sharecast News) - Drug discovery and development company ImmuPharma announced positive progress in its late-stage P140 clinical programme on Tuesday, for patients with chronic idiopathic demyelinating...
-
ImmuPharma upbeat after meeting with US partner Avion
11 November 2022 13:04
(Sharecast News) - Drug discovery and development specialist ImmuPharma updated the market on a recent meeting in Atlanta with its United States partner Avion Pharmaceuticals on Friday, for strategic...
-
ImmuPharma's US partner receives FDA response on Lupuzor
14 September 2022 13:51
(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Wednesday that its US partner for 'Lupuzor', Avion Pharmaceuticals, has received a written response from...
-
ImmuPharma making final preparations for Lupuzor phase 3 trial
4 May 2022 13:03
(Sharecast News) - Specialist drug discovery and development company ImmuPharma said on Wednesday that final preparations were now underway to progress 'Lupuzor' into its new, optimised...
-
ImmuPharma surges on success in latest trial of lupus treatment
13 April 2022 13:54
(Sharecast News) - Specialist drug discovery and development company ImmuPharma reported positive data from its 'Lupuzor' pharmacokinetic study on Wednesday, as part of the new, optimised...
-
ImmuPharma updates plan for trials of lupus treatment Lupuzor
7 February 2022 13:13
(Sharecast News) - Drug discovery and development specialist ImmuPharma updated the market on the pharmacokinetic study of 'Lupuzor' on Monday, as part of the new, optimised international phase 3...
Company announcements Announcements
-
Breakthrough Findings into Autoimmune Diseases
9 January 2025 07:00
Immupharma
-
IMM at JP MORGAN CONFERENCE & BIOTECH SHOWCASE
8 January 2025 07:00
Immupharma
-
Change of Auditor
23 December 2024 07:00
Immupharma
-
Holding(s) in Company
10 December 2024 14:36
Immupharma
-
Appointment of Company Secretary
4 December 2024 07:00
Immupharma
-
Holding(s) in Company
6 August 2024 13:41
Immupharma
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.